Sonepcizumab

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NameSonepcizumab
Drug Alias NameAnti S1P monoclonal antibody (Lpath)Sonepcizumab/LT1009SphingomabASONEPiSONEP +[6] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody human
Mechanisms of ActionSphingosine 1 phosphate inhibitorsAngiogenesis inhibitors
TargetsSphingosine 1 phosphate
Therapy Area/IndicationsSolid tumoursRetinal DetachmentMacular Degeneration +[4] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusDiscontinued (Phase 2 Clinical)
Highest Status in ChinaN/A
Originator CompaniesLpath Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesLpath Inc
Active IndicationsN/A
Inactive IndicationsSolid tumoursRetinal DetachmentMacular Degeneration +[4] 

Other Information

ATC CodeN/A
Related LinksN/A